SundayTrader
04 Jun 2018
Re: the Guardian Don't myself see the issue here. Use of wet wipes for specialist sterilisation of medical equipment is a tiny fraction of hospital usage, let alone the vast domestic usage. And, as the article points out, the modern hospital can't run without wet wipes. It seems to be mostly about the contribution to sewage blockages, where the primary cause is excessive, and often illegal, disposal of fat from fast food restaurants into the drains - causes huge problems for the water companies.
Chicken Lips
12 May 2018
the Guardian The Guardia has an article that references NHS chemical wipes, assume its Tristel. Any views out there about the current negative news about wipes and Govt announcements to eliminate single wipes? NHS/Hospitals are differentKFC kicked it all off apparently [link]
seadoc
24 Apr 2018
Re: Great news! "(Btw; where are all other fellow investors ? 😯 ) "Still in Wales,Seadoc
Chicken Lips
23 Apr 2018
Re: Great news! Game changer!
sporty investor
23 Apr 2018
Great news! Fantastic news from the company. Approval from USA agency! Hopefully, Profits from USA sales will be big in numbers. It has been worth the wait.(Btw; where are all other fellow investors ? 😯 )
sporty investor
26 Mar 2018
Entering American markets. Welcome news. Tristel entering American healthcare products market.Unfortunately, the timing of announcement this great news isn’t correct. At other times, this could have propelled the share price in a big way.
sporty investor
20 Feb 2018
Any news about results? Any news/updates from today’s ‘ Investors results presentation’?Thank
winningstreak
20 Feb 2018
Re: Snouts in trough? I like what the Company does, but I do not like the verygenerous options granted to the directors. Profits aheadcould be considerably damaged by options, IMO.ws
brightonboyaswell
24 Jan 2018
here is the announcement not showing on iii Study shows comparable efficacy of Tristel WipesWed, 24th Jan 2018 07
0RNS Number : 7135CTristel PLC24 January 2018 Tristel plc ("Tristel" or "the Company"
Study shows comparable efficacy of Tristel Wipes Tristel's chlorine dioxide wipes are validated as a viable alternative to peracetic acid disinfectants for the high-level disinfection of flexible nasendoscopes Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that a study conducted at the Khoo Tech Puat Hospital, Singapore, has concluded that the Tristel Wipe has comparable efficacy to a world leading peracetic acid high-level disinfectant (Rapicide; Cantel Medical, New Jersey, USA), and provides significant other advantages to a hospital. The study has been published in the International Journal of Otorhinolaryngology and Head and Neck Surgery (Gan YJ et al. Int J. Otorhinolaryngol Head Neck Surg. 2018 Jan; 4(1):18-23). Cantel is one of the world's largest dedicated infection prevention companies quoted on the NYSE. The study took place in the Ear, Nose and Throat clinic during 2014. One hundred patients volunteered to participate and for each endoscopic examination one nasendoscope disinfected by Rapicide and one nasendoscope disinfected by a Tristel Wipe was used to scope each nasal passage of the patient. From swabbing each nasendoscope pre and post disinfection to reveal evidence of bacterial contamination the study concludes that Rapicide and the Tristel Wipe are statistically equivalent in terms of efficacy. In addition to being comparable with Rapicide the study identifies other significant advantages of the Tristel Wipe. These benefits are rapid turnaround of the nasendoscope (2-3 minutes for Tristel versus 20 minutes for Rapicide) which means the clinic can see more patients in a day with fewer nasendoscopes; Tristel's safety from a health standpoint, and the Tristel Wipe's portability which means that it can be easily taken to the emergency department or to the wards. This is important as even though most ENT departments are out-patient areas, frequently in-patients carry MRSA, vancomycin-resistant Enterococci (VRE), and even tuberculosis, and need to have a nasendoscopy. The Tristel Wipe can easily be taken to them to enable the examination. The Tristel Wipes System is a unique, patented decontamination method for non-lumened endoscopes and ultrasound probes. It has been a very significant sales success for the Company globally. Worldwide sales of the Wipes System in the financial year ending June 2017 were £11.5m. Paul Swinney, CEO, comments: "We are pleased to see the publication in a peer-reviewed journal of yet another study comparing our Wipe with a leading peracetic acid high-level disinfectant - Cantel's Rapicide product. Peracetic acid is the most widely used high-level disinfectant chemistry in Europe and probably the United States also. The results affirm the key advantages of our Wipes over alternative chemistries and disinfection methods. These advantages are the level and speed of kill and the capability of our Wipe System to be deployed anywhere within a healthcare setting without the need for power, water and space. This is the thirty first peer-reviewed and published scientific paper featuring Tristel products - a body of evidence of our products' attributes that forms one of our Company's key strengths."
Chicken Lips
03 Jan 2018
Re: Hoping for the better Happy New YearI got a little worried with the SP drift in the run up to he 'Santa Rally' when the reindeer were heading south.There has been volatility in the SP for some time, not surprising when you consider the rise but the recent dips have hit my bottom line and I have sold down a percentage of my stock as we still seem to be in a downward trend.Can I say that I will buy back should this drop further which seems likely with no news.
sporty investor
03 Jan 2018
Hoping for the better Happy New Year to all.No updates from the company and no new posts here for a while.Hoping for encouraging news from the US side. Has anyone got any more information?
II Editor
29 Nov 2017
NEW ARTICLE: Share Sleuth: Be wary of excessive executive pay "Events at LSE:TSTL:Tristel are a reminder that complicated remuneration schemes masking inflated executive pay extend way beyond the big companies and 'fat cats' that make it into the headlines. Boards showing restraint, in my opinion, are ..."[link]
II Editor
10 Nov 2017
NEW ARTICLE: Is superstar Tristel unbeatable? "I'm wondering about Tristel, Richard. You named it as one of the 'popular' shares in the Share Sleuth portfolio. And by popular I sensed you meant it may be overpriced.Hmmm. Kind of. There's lots of speculation in the price. At 280p it values the ..."[link]
sporty investor
02 Nov 2017
Re: Snouts in trough? Hope this "rewards" will not have any negative impact on the share price in the coming days.
winningstreak
02 Nov 2017
Re: Snouts in trough? Re previous message, I should add that the vesting target prices arefair an correct, IMO. However, the total value would amount to above£4m, which is to all intents and purposes a very large bite out of profits! ws
